Henry Schein (HSIC) is set to report a growth in earnings in the next week, capturing investor attention. HSIC's strategic partnership with KKR is evolving, with the latter making a strategic investment and resulting in changes at the board level. HSIC's price target has been reduced to $77 by Piper Sandler while facing adjustments by BofA. In spite of lowered price targets and a 3.9% drop in shares since the last earnings report, HSIC anticipates strong Q1 2025 earnings. Mixed fundamentals have resulted in negative market sentiment. A notable achievement for the company involves the validation of its net-zero science-based targets, emphasizing their commitment towards sustainability. HSIC continues to stay on top of its debt while broadly meeting Q4 earnings estimates. Ananym Capital, an activist investor, is pushing for changes at Henry Schein. HSIC, meanwhile, moves forward with acquisitions, including that of Acentus and is continuously involved with investor conferences. Also, clinical advancements like the digital revolution in dentistry, showcase their ongoing commitment towards innovation. A change of plans, involving new executive severance and control schemes, compliments their leadership transition and restructuring for growth strategy.
Henry Schein HSIC News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Fri, 02 May 2025 20:57:31 GMT -
Rating -4
- Innovation 5
- Information 8
- Rumor -3
